Coinbase Slammed After Earnings as Analysts Cut Targets Across the Board

Coinbase Global reported Q3 results on October 29 and the Street's reaction was swift: the stock fell 11.6% the following day, seven analysts trimmed price targets on the same morning, and the shares now trade at $143.54, nearly 32% below the consensus mean.

The analyst response tells the clearest story about where professional opinion sits. Almost every major firm cut its target on October 30, though none changed their ratings, a distinction worth noting. Goldman Sachs was the sharpest mover, with analyst James Yaro lowering his target from $244 to $210 while keeping a Buy. JP Morgan's Kenneth Worthington trimmed from $189 to $187, also retaining Overweight. Barclays went furthest in the bear direction, cutting from $149 to $120 with an Underweight already in place. The firms that held their targets, HC Wainwright and BTIG at $240, and Cantor Fitzgerald at $212, were outnumbered by those pulling back. The consensus mean now stands at $210.85, implying 47% upside from the current price, a gap that is arithmetically large but reflects a Street that is selectively less confident than it was a week ago rather than turning outright bearish.

The bull and bear cases are sharply drawn. Bulls point to Q3 revenue near $1.2 billion, adjusted EBITDA of $250 million, and Coinbase gaining share in a softer market: spot volumes fell only 2% quarter-on-quarter against a broader crypto market decline of 7%. Custody is another anchor, with roughly 12% of global onchain assets held on the platform and more than 200 clients using the developer platform. Bears counter that a 10.7% cut to stablecoin revenue drove the subscription and services segment estimate 5.7% lower, and management has moderated its second-half and full-year 2027 assumptions, with the FY27 EBITDA estimate dropping 8%. Valuation adds friction: the price-to-earnings multiple has compressed sharply, falling more than 43 points over the past 30 days to 72.8x, and the EV/EBITDA multiple is 17x. The EPS momentum factor score ranks in the 100th percentile over 30 days and 99th on surprise, but the 90-day momentum sits at just the 28th percentile, a sign the forward revision cycle has not been uniformly positive.

Short interest has actually eased through the earnings episode. ORTEX estimates shorts fell to 22.6 million shares, or 9.9% of free float, as of October 29. That is down 8.1% week-on-week and down 19.4% over the month, meaning bears were paring back into the print rather than pressing into it. The borrow market remains loose: availability is running at 604%, far above the 52-week trough of 255%, and cost to borrow is 0.42%, barely changed on the week. The ORTEX short score has also drifted lower this week, declining from 54.3 on October 20 to 51.1 on October 29, consistent with the easing short positioning. Options are equally calm: the put/call ratio is 0.78, almost exactly in line with its 20-day average of 0.780, and the z-score of 0.18 is essentially flat. None of these signals point to a short squeeze or a positioning-driven second leg lower.

The peer group moved in the same direction. SBET fell 11.7% on the week. HOOD dropped 10.6%. BLSH was hit hardest at 15.3%. The sell-off in crypto-adjacent equities was broad rather than specific to Coinbase, though the 12.7% weekly decline in COIN placed it roughly in line with the worst performers in the group. Retail attention, measured by Wikipedia page views against Coinbase's own 90-day history, came in with a z-score of 1.4 as of October 21, suggesting above-average public interest even before the earnings release.

Insider selling through the period was exclusively under pre-arranged 10b5-1 plans, with Marc Andreessen executing scheduled sales in September and early October and CFO Alesia Haas selling shares on September 21. Net insider value over the past 90 days is negative $22.6 million, but the planned nature of every transaction reduces its signal value as a directional read on management conviction.

The next earnings date is February 11, 2027, giving the market 103 days to decide whether the post-results gap lower reprices the stock fairly or overshoots given the operational gains in market share and institutional custody the company reported alongside the disappointing subscription guidance.